Completed OBSERVATIONAL NCT01604018

An Optional Two Year Follow Up Study to Study CP005A

An Optional Two Year Follow Up Study to Evaluate the Continued Efficacy of Cat-PAD ToleroMune Peptide Immunotherapy in Cat Allergic Subjects Following Challenge to Cat Allergen in an Environmental Exposure Chamber

Sponsor: Adiga Life Sciences, Inc.

Conditions Cat Allergy Rhinoconjunctivitis

Updated 6 times since 2017 Last updated: May 23, 2012 Started: Feb 29, 2012 Primary completion: Apr 30, 2012 Completion: Apr 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01604018, this observational or N/A phase trial focuses on Cat Allergy and Rhinoconjunctivitis and remains completed. Sponsored by Adiga Life Sciences, Inc., it has been updated 6 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Feb 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Adiga Life Sciences, Inc.
Cetero Research, Toronto
Circassia Limited

Data source: Circassia Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mississauga, Canada